These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 38431475)

  • 1. COPS8 promotes hepatocellular carcinoma progression through the PI3K/AKT/mTOR pathway.
    Yan X; Li Z; Tian Q; Zhang Y
    Asian J Surg; 2024 Jun; 47(6):2947-2949. PubMed ID: 38431475
    [No Abstract]   [Full Text] [Related]  

  • 2. Role of regulatory miRNAs of the PI3K/AKT/mTOR signaling in the pathogenesis of hepatocellular carcinoma.
    Rahmani F; Ziaeemehr A; Shahidsales S; Gharib M; Khazaei M; Ferns GA; Ryzhikov M; Avan A; Hassanian SM
    J Cell Physiol; 2020 May; 235(5):4146-4152. PubMed ID: 31663122
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AURKB targets DHX9 to promote hepatocellular carcinoma progression via PI3K/AKT/mTOR pathway.
    Zhu G; Luo L; He Y; Xiao Y; Cai Z; Tong W; Deng W; Xie J; Zhong Y; Hu Z; Shan R
    Mol Carcinog; 2024 Sep; 63(9):1814-1826. PubMed ID: 38874176
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overexpression of microRNA-133b is associated with the increased survival of patients with hepatocellular carcinoma after curative hepatectomy: Involvement of the EGFR/PI3K/Akt/mTOR signaling pathway.
    Wang X; Zeng J; Wang L; Zhang X; Liu Z; Zhang H; Dong J
    Oncol Rep; 2017 Jul; 38(1):141-150. PubMed ID: 28586051
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CXCL14 inhibits the growth and promotes apoptosis of hepatocellular carcinoma cells via suppressing Akt/mTOR pathway.
    Bi J; Liu Q; Sun Y; Hu X; He X; Xu C
    J Recept Signal Transduct Res; 2021 Dec; 41(6):593-603. PubMed ID: 33108937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIF-2α upregulation mediated by hypoxia promotes NAFLD-HCC progression by activating lipid synthesis via the PI3K-AKT-mTOR pathway.
    Chen J; Chen J; Huang J; Li Z; Gong Y; Zou B; Liu X; Ding L; Li P; Zhu Z; Zhang B; Guo H; Cai C; Li J
    Aging (Albany NY); 2019 Dec; 11(23):10839-10860. PubMed ID: 31796646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [EEF1A2 inhibits the p53 function in hepatocellular carcinoma via PI3K/AKT/mTOR-dependent stabilization of MDM4].
    Longerich T
    Pathologe; 2014 Nov; 35 Suppl 2():177-84. PubMed ID: 25394965
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MYO18B promotes hepatocellular carcinoma progression by activating PI3K/AKT/mTOR signaling pathway.
    Zhang Z; Zhu J; Huang Y; Li W; Cheng H
    Diagn Pathol; 2018 Nov; 13(1):85. PubMed ID: 30390677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of novel therapeutic targets in the PI3K/AKT/mTOR pathway in hepatocellular carcinoma using targeted next generation sequencing.
    Janku F; Kaseb AO; Tsimberidou AM; Wolff RA; Kurzrock R
    Oncotarget; 2014 May; 5(10):3012-22. PubMed ID: 24931142
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elevated PDK1 Expression Drives PI3K/AKT/MTOR Signaling Promotes Radiation-Resistant and Dedifferentiated Phenotype of Hepatocellular Carcinoma.
    Bamodu OA; Chang HL; Ong JR; Lee WH; Yeh CT; Tsai JT
    Cells; 2020 Mar; 9(3):. PubMed ID: 32197467
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alpha1-ACT Functions as a Tumour Suppressor in Hepatocellular Carcinoma by Inhibiting the PI3K/AKT/mTOR Signalling Pathway via Activation of PTEN.
    Zhu H; Liu Q; Tang J; Xie Y; Xu X; Huang R; Zhang Y; Jin K; Sun B
    Cell Physiol Biochem; 2017; 41(6):2289-2306. PubMed ID: 28456796
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ruscogenin suppressed the hepatocellular carcinoma metastasis via PI3K/Akt/mTOR signaling pathway.
    Hua H; Zhu Y; Song YH
    Biomed Pharmacother; 2018 May; 101():115-122. PubMed ID: 29477471
    [TBL] [Abstract][Full Text] [Related]  

  • 13. G-CSF promotes the development of hepatocellular carcinoma by activating the PI3K/AKT/mTOR pathway in TAM.
    Cao H; Wang S
    Aging (Albany NY); 2024 Jul; 16(13):10799-10812. PubMed ID: 38967628
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SOCS5 inhibition induces autophagy to impair metastasis in hepatocellular carcinoma cells via the PI3K/Akt/mTOR pathway.
    Zhang M; Liu S; Chua MS; Li H; Luo D; Wang S; Zhang S; Han B; Sun C
    Cell Death Dis; 2019 Aug; 10(8):612. PubMed ID: 31406106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Upregulation of UBE2Q1 via gene copy number gain in hepatocellular carcinoma promotes cancer progression through β-catenin-EGFR-PI3K-Akt-mTOR signaling pathway.
    Zhang B; Deng C; Wang L; Zhou F; Zhang S; Kang W; Zhan P; Chen J; Shen S; Guo H; Zhang M; Wang Y; Zhang F; Zhang W; Xiao J; Kong B; Friess H; Zhuge Y; Yan H; Zou X
    Mol Carcinog; 2018 Feb; 57(2):201-215. PubMed ID: 29027712
    [TBL] [Abstract][Full Text] [Related]  

  • 16. VersicanV1 promotes proliferation and metastasis of hepatocellular carcinoma through the activation of EGFR-PI3K-AKT pathway.
    Zhangyuan G; Wang F; Zhang H; Jiang R; Tao X; Yu D; Jin K; Yu W; Liu Y; Yin Y; Shen J; Xu Q; Zhang W; Sun B
    Oncogene; 2020 Feb; 39(6):1213-1230. PubMed ID: 31605014
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ropivacaine suppresses tumor biological characteristics of human hepatocellular carcinoma via inhibiting IGF-1R/PI3K/AKT/mTOR signaling axis.
    Zhang R; Lian Y; Xie K; Cai Y; Pan Y; Zhu Y
    Bioengineered; 2021 Dec; 12(2):9162-9173. PubMed ID: 34696683
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unveiling the role of UPF3B in hepatocellular carcinoma: Potential therapeutic target.
    Hou B; Shu M; Liu C; Du Y; Xu C; Jiang H; Hou J; Chen X; Wang L; Wu X
    Cancer Sci; 2024 Aug; 115(8):2646-2658. PubMed ID: 38889220
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Catalpol synergistically potentiates the anti-tumour effects of regorafenib against hepatocellular carcinoma via dual inhibition of PI3K/Akt/mTOR/NF-κB and VEGF/VEGFR2 signaling pathways.
    El-Hanboshy SM; Helmy MW; Abd-Alhaseeb MM
    Mol Biol Rep; 2021 Nov; 48(11):7233-7242. PubMed ID: 34596810
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined targeting of AKT and mTOR synergistically inhibits proliferation of hepatocellular carcinoma cells.
    Grabinski N; Ewald F; Hofmann BT; Staufer K; Schumacher U; Nashan B; Jücker M
    Mol Cancer; 2012 Nov; 11():85. PubMed ID: 23167739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.